Please login to the form below
Replagal
This page shows the latest Replagal news and features for those working in and with pharma, biotech and healthcare.
Amicus gets NICE green light for Fabry drug
Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta) and Shire's Replagal
Latest news
-
NICE backs Amicus Therapeutics’ Galafold
and Shire's Replagal (agalsidase alfa).
-
GSK gene therapy tops CHMP recommendations
The drug could offer a patient-friendly alternative to injectable Fabry therapies such as Sanofi/Genzyme's Fabrazyme (agalsidase beta) and Shire's Replagal (agalsidase alfa).
-
Sanofi gains accelerated review for rare disease drug
But even though catering for a small patient population (around 10, 000 people are thought to have the disorder globally), the firm has competition in Shire's Replagal (agalsidase alfa).
-
AbbVie coaxes Shire into discussions with sweetened offer
as Elaprase (idursulfase) for Hunter syndrome and Replagal (agalsidase alfa) for Fabry disease.
-
The moving parts of orphan drug development
The company already had its own orphan brands such as Replagal (agalsidase alfa) for Fabry disease, Hunter's syndrome treatment Elaprase (idursulfase) and Vpriv (velaglucerase alfa) for Gaucher disease, when it
More from news
Approximately 2 fully matching, plus 15 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Business Director
-
Competitive Salary Offered
- Business Development Director – Health Education
-
excellent commission
-
Account Director
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
- Account Manager- Healthcare Advertising
-
Negotiable
-
Experienced Medical Writers
-
Competitive Salary and Benefits
- Account Manager- Healthcare Advertising
-
Negotiable
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Manager
-
Negotiable
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
Subscribe to our email news alerts
- FDA takes aim at pharma’s biosimilar-delaying tactics
- Circassia seeks shift to AIM after failing LSE criteria
- Beneluxa: the future of European market access?
- Fishawack acquires Blue Latitude Health
- Axovant drops last ‘legacy’ drug to focus on gene therapies
- FDA clears Sandoz and Pear’s Opioid Use Disorder app
PMHub
Cello Health Insight
Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
